Personalized Lung Cancer Vaccine Shows Early Promise
A new trial shows that combining a custom vaccine with immunotherapy may help some lung cancer patients manage their disease.
Updated on Oct. 24, 2026 in Cancer
Live Poll
Should experimental cancer vaccines be prioritized for fast-tracked clinical development in the healthcare system?
Researchers recently reported preliminary results from a phase 1b/2a trial investigating a personalized mRNA cancer vaccine, LK101, combined with the immunotherapy drug tislelizumab. The combination treatment is being studied for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Why it matters
This approach aims to improve survival outcomes in lung cancer by using a vaccine to prime the immune system to recognize tumor-specific neoantigens while simultaneously using PD-1 blockade to overcome tumor-driven immune suppression.
In a phase 1b/2a trial of 25 patients with advanced lung cancer, the vaccine LK101 combined with tislelizumab resulted in a 19.0% objective response rate and 95.2% disease control rate. These preliminary findings show a 30-fold median increase in T-cell activity, though the trial is still ongoing.
The players
Tislelizumab
An immunotherapy agent known as a PD-1 inhibitor that blocks a pathway cancer cells use to evade immune system detection.
The details
The vaccine is created by using dendritic cells transfected with patient-specific mRNA that encodes 30 distinct tumor neoantigens, delivered through electroporation. Once administered via intradermal injections, these cells train the patient's own T cells to identify and attack cancer cells. This specific cellular response is designed to function in tandem with tislelizumab, which prevents cancer cells from deactivating immune cells, thereby maintaining an active antitumor defense.
Timeline
March 31, 2026 was the data cutoff date for the trial analysis.
October 23-27, 2026 marked the presentation of results at the 2026 ESMO Congress.
Health Landscape
This study follows the industry trend of combining personalized mRNA vaccines with immune checkpoint inhibitors to broaden the efficacy of immunotherapy. It positions this therapeutic combination alongside other experimental approaches designed to overcome the limited response rates seen with standard PD-1 blockade in lung cancer.
These results are preliminary, meaning they do not yet represent a standard clinical treatment option for patients with non-small cell lung cancer. Patients interested in how emerging immunotherapy combinations might fit into their care plan should discuss the eligibility criteria for future clinical trials with their oncologist.
The takeaway
The study suggests that personalized vaccines may help sensitize tumors to existing immunotherapy, potentially increasing the number of patients who respond to treatment. Patients should continue to monitor new developments in trial outcomes and consult with specialists regarding experimental immunotherapy options.
Further reading
For more on the evolving field of lung cancer treatments, visit our Cancer section.
More information
View full study details on the Clinical trial registry for LK101.
Source note: This article includes information reported by OncLive.
Live Poll
Should experimental cancer vaccines be prioritized for fast-tracked clinical development in the healthcare system?
